文献速递神经肿瘤功能神经外科

吡仑帕奈对伴胶质瘤的药物难治性癫痫的发作反应:早期观察

Seizure response to perampanel in drug-resistant epilepsy with gliomas: early observations.
PubMed 文献 · J Neurooncol · 2017-05-10

在12例伴低级别和高级别胶质瘤的药物难治性癫痫患者中测试AMPA受体阻断剂吡仑帕奈(PER),中位年龄41岁,9男3女,中位随访6个月。9例(75%)出现客观发作反应:3例发作频率下降50%,6例无发作;6例出现副作用。8例中6例认知速度测试(CTCS)改善,与合并抗癫痫药减量相关。最终中位剂量8 mg(范围2至12 mg)。

要点

  • 12例伴胶质瘤的药物难治性癫痫患者中9例(75%)对吡仑帕奈出现客观发作反应。
  • 客观发作反应包括3例发作频率下降50%和6例无发作。
  • 6例出现副作用;8例中6例认知速度测试改善,与合并抗癫痫药减量相关。

核心结论

  • 12例伴胶质瘤的药物难治性癫痫患者中9例(75%)对吡仑帕奈出现客观发作反应,可能被解读为AMPA阻断继发肿瘤反应的替代标志物,有待MR影像进一步确认。
  • 这些结果值得进一步研究吡仑帕奈对胶质瘤肿瘤活性的作用。

研究设计与样本

  • 在低级别和高级别胶质瘤伴药物难治性癫痫患者中测试AMPA受体阻断剂吡仑帕奈(PER)。
  • 共纳入12例患者,中位年龄41岁,9男3女,中位随访6个月。
  • 发作反应定义为发作频率下降50%或无发作;认知功能采用计算机认知速度测试(CTCS)检查。
  • 治疗策略包括一旦观察到无发作反应即减少剂量或停用一种或多种合并抗癫痫药。

主要发现

  • 12例中9例(75%)出现客观发作反应:3例发作频率下降50%,6例无发作。
  • 6例患者出现副作用。
  • 8例接受CTCS检查者中6例认知功能改善,与合并抗癫痫药减量相关。
  • 吡仑帕奈最终中位剂量为8 mg(范围2至12 mg)。

关键数值与推荐

  • 发作反应定义为发作频率下降50%或无发作。
  • 客观发作反应在12例中9例(75%)观察到:50%发作反应3例,无发作6例。
  • 吡仑帕奈最终中位剂量8 mg(范围2至12 mg)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文结论指出这些结果值得进一步研究吡仑帕奈对胶质瘤肿瘤活性的作用。
  • 原文结论指出客观发作反应可能被解读为AMPA阻断继发肿瘤反应的替代标志物,有待MR影像进一步确认。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Drug-resistant epilepsy (DRE) occurs commonly in gliomas, possibly due to a shared mechanism of AMPA-activation involving both seizure activity and tumor growth. We tested the AMPA-receptor blocker perampanel (PER) in patients with DRE in low- and high-grade gliomas. Seizure response was defined as 50% drop in seizure frequency or as seizure-freedom. Cognitive function was examined by computerized test on cognitive speed (CTCS), which is sensitive to the type of cognitive dysfunction associated with epilepsy and use of anticonvulsants. Treatment policy included reduction of dose or discontinuation of one or more concurrent AEDs, once a seizure-free response was observed. Twelve patients were included patients, median age 41 years, 9 men versus 3 women and 6 months median duration of follow-up. An objective seizure response (75%) was observed in 9 (75%) out of 12 patients: 50%-seizure response in 3, seizure-freedom in 6, which is plainly more than seen with other types of DRE. Side-effects occurred in six patients. Cognitive function as examined by CTCS improved in six out of eight associated withlowering of concurrent AEDs. The final median dose of PER was 8 mg (varying between 2 and 12 mg). These results of an objective seizure response in 9 (75%) out of 12 patients treated by PER in DRE may be interpreted as a surrogate-marker of tumor response secondary to AMPA blockade, advancing confirmation by MR imaging. These results warrant further study of PER on tumor activity in gliomas.

来源:J Neurooncol,查看原文。版权归原作者所有。

引用

  1. Vecht C, Duran-Peña A, Houillier C, et al. Seizure response to perampanel in drug-resistant epilepsy with gliomas: early observations. J Neurooncol. 2017. PMID: 28492978. doi:10.1007/s11060-017-2473-1

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。